Supplementary Methods from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Oza AM., Matulonis UA., Alvarez Secord A., Nemunaitis J., Roman LD., Blagden SP., Banerjee S., McGuire WP., Ghamande S., Birrer MJ., Fleming GF., Markham MJ., Hirte HW., Provencher DM., Basu B., Kristeleit R., Armstrong DK., Schwartz B., Braly P., Hall GD., Nephew KP., Jueliger S., Oganesian A., Naim S., Hao Y., Keer H., Azab M., Matei D.